Apellis Pharmaceuticals
APLS
Last Price
52 Week Range
$16.10 - $40.45
Next Earnings Date
May 06 2026 (Estimate)
Next Earnings Date
May 06 2026 (Est.)
Last Price
Apellis Pharmaceuticals SEC Filings
Company Name | Form Type | Filed | View |
|---|---|---|---|
Apellis Pharmaceuticals, Inc. | 8-K | March 31, 2026 | |
Apellis Pharmaceuticals, Inc. | 8-K | March 2, 2026 | |
Apellis Pharmaceuticals, Inc. | 10-K | February 24, 2026 | |
Apellis Pharmaceuticals, Inc. | 8-K | January 12, 2026 | |
Apellis Pharmaceuticals, Inc. | 10-Q | October 30, 2025 | |
Apellis Pharmaceuticals, Inc. | 10-Q | July 31, 2025 | |
Apellis Pharmaceuticals, Inc. | 8-K | July 1, 2025 | |
Apellis Pharmaceuticals, Inc. | 8-K | June 4, 2025 | |
Apellis Pharmaceuticals, Inc. | 10-Q | May 7, 2025 | |
Apellis Pharmaceuticals, Inc. | DEFA14A | April 23, 2025 | |
Apellis Pharmaceuticals, Inc. | ARS | April 23, 2025 | |
Apellis Pharmaceuticals, Inc. | DEF 14A | April 23, 2025 | |
Apellis Pharmaceuticals, Inc. | 8-K | April 21, 2025 | |
Apellis Pharmaceuticals, Inc. | 10-K | February 28, 2025 | |
Apellis Pharmaceuticals, Inc. | 8-K | January 13, 2025 | |
Apellis Pharmaceuticals, Inc. | 10-Q | November 5, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | August 8, 2024 | |
Apellis Pharmaceuticals, Inc. | 10-Q | August 1, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | June 5, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | May 14, 2024 | |
Apellis Pharmaceuticals, Inc. | 10-Q | May 7, 2024 | |
Apellis Pharmaceuticals, Inc. | DEFA14A | April 26, 2024 | |
Apellis Pharmaceuticals, Inc. | ARS | April 26, 2024 | |
Apellis Pharmaceuticals, Inc. | DEF 14A | April 26, 2024 | |
Apellis Pharmaceuticals, Inc. | 10-K | February 27, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | February 27, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | January 22, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | January 8, 2024 | |
Apellis Pharmaceuticals, Inc. | 8-K | December 14, 2023 | |
Apellis Pharmaceuticals, Inc. | 8-K | December 1, 2023 |
Load More...
Gainify
Features
Platform
Resources
Learn
Socials
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
© 2026 Gainify. All rights reserved.